Equity Profile
Pre-Earnings Brief
Summit Therapeutics Inc. (SMMT) is a biotechnology company focused on developing novel medicines for serious diseases....
Earnings Per Share (EPS)
EPS is a key indicator of profitability and will show how well the company is managing its costs and revenues.
Revenue Growth
Revenue growth is crucial for assessing the company's market demand and overall business health.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
3Q
EPS Beat Rate
88%
Avg EPS Surprise
+19.76%
Avg Stock Reaction
-4.23%
In Q1-2026, Summit Therapeutics reported an EPS of -$0.15, which was better than the expected -$0.33, resulting in a positive surprise of nearly 55%. The stock reacted positively, gaining over 3% the following day.
Management Promises & Guidance
Overall expectations for Summit Therapeutics are mixed, with a history of beating EPS estimates but uncertainty around revenue figures. Investors will be keenly watching for any updates on product development and market strategy.
Bull Case
If the company continues its trend of beating EPS estimates, it could signal strong operational efficiency and investor confidence, potentially driving the stock higher.
Bear Case
Conversely, if the company fails to meet expectations or provides disappointing guidance, it could lead to a sell-off, particularly given the high implied volatility in the options market.
Earnings Per Share (EPS)
N/AEPS is a key indicator of profitability and will show how well the company is managing its costs and revenues.
Revenue Growth
N/ARevenue growth is crucial for assessing the company's market demand and overall business health.
Expectations
The print will turn on these two things.
Q1
What will be the EPS for Q2-2026?
Given the company's history of beating EPS estimates, this figure will be critical in determining investor sentiment and stock performance.
Q2
What updates will management provide on product development?
Insights into product pipelines and market strategies can significantly influence future revenue projections and investor confidence.
Edge
Why consensus could be wrong
The Street may be underestimating the potential for Summit to exceed EPS expectations again, given its recent track record of surprises.
Supporting Evidence
Summit has an 88% EPS beat rate over the last eight quarters, indicating strong operational performance.
The options market is pricing in a high volatility move, suggesting that investors expect significant news or developments.
Key Risk
If the EPS comes in below -$0.20, it could undermine the bullish sentiment surrounding the stock.
Edge
Pre-commit to what would confirm each case.
The core thesis revolves around whether Summit Therapeutics can maintain its trend of beating EPS estimates while providing positive guidance on revenue and product development.
Bull Confirmed If
An EPS of -$0.10 or better would confirm the bull case, indicating strong operational performance.
Bear Confirmed If
An EPS worse than -$0.20 would confirm the bear case, raising concerns about the company's financial health.
Pre-Earnings Positioning
Implied Move
±54.83%
Historical Avg
±5.8%
The options market is pricing in a significant move, suggesting that investors expect substantial volatility around the earnings announcement.
Options are pricing ±54.8% while SMMT has averaged ±5.8% over the last 8 prints — setup is pricing rich.
ATM IV
1.0%
30d HV
120.5%
Edge
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
n=30Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.5%, with a raw directional average of +0.7% (modestly positive historical bias).
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Summit beats expectations, history suggests the stock could rise by around 5.8%, confirming strong operational performance.
In-Line / Cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
A miss could lead to a decline of approximately 1.4%, reflecting investor disappointment and concerns over future performance.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Kymera Therapeutics, Inc.